Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology.
Henderson
Colin J
CJ
Cancer Research UK, Molecular Pharmacology Unit Biomedical Research Centre, Ninewells Hospital & Medical School, Dundee DD1 9SY, Scotland, United Kingdom. colin.henderson@cancer.org.uk
Wolf
C Roland
CR
D000818:Animals; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics* / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D017353:Gene Deletion; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D051267:NF-E2-Related Factor 2; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D018336:Receptors, Aryl Hydrocarbon / Q000235:genetics / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics / Q000378:metabolism; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism
D004268:DNA-Binding Proteins; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; C495636:Nfe2l2 protein, mouse; D004364:Pharmaceutical Preparations; D018336:Receptors, Aryl Hydrocarbon; D018160:Receptors, Cytoplasmic and Nuclear; D015534:Trans-Activators; D014157:Transcription Factors; D003577:Cytochrome P-450 Enzyme System